Trial Profile
A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Runimotamab (Primary) ; Tocilizumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 10 Apr 2024 Planned End Date changed from 30 Apr 2024 to 31 May 2025.
- 10 Apr 2024 Planned primary completion date changed from 30 Apr 2024 to 31 May 2025.
- 10 Apr 2024 Status changed from recruiting to active, no longer recruiting.